Actionnariat et activité des initiés pour PTC Therapeutics, Inc. (PTCT): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $67.25 |
| Capitalisation | $5.6B |
| Bourse | NASDAQ |
| Pays | US |
Transactions d'Initiés Récentes
| Date | Initié | Type | Actions | Valeur |
|---|---|---|---|---|
| 2026-09-09 | SCHMERTZLER MICHAEL | S-Sale | 9,428 | $639K |
| 2026-09-09 | SCHMERTZLER MICHAEL | S-Sale | 572 | $39K |
| 2026-09-10 | SCHMERTZLER MICHAEL | S-Sale | 10,000 | $673K |
| 2026-08-26 | SCHMERTZLER MICHAEL | S-Sale | 6,874 | $500K |
| 2026-08-26 | SCHMERTZLER MICHAEL | S-Sale | 5,626 | $412K |
| 2026-08-27 | SCHMERTZLER MICHAEL | S-Sale | 11,890 | $851K |
| 2026-08-27 | SCHMERTZLER MICHAEL | S-Sale | 610 | $44K |
| 2026-08-19 | SCHMERTZLER MICHAEL | S-Sale | 5,335 | $389K |
| 2026-08-19 | SCHMERTZLER MICHAEL | S-Sale | 7,165 | $528K |
| 2026-08-20 | SCHMERTZLER MICHAEL | S-Sale | 9,419 | $667K |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $231.7M | $191.2M | $227.6M | $288.0M | $208.8M | $189.7M | $279.8M | $594.0M | $779.7M | $984.6M |
| Placements à Court Terme | 0 | 0 | 0 | $398.5M | $894.8M | $583.7M | $130.9M | $282.7M | $360.0M | $960.7M |
| Créances | $24.9M | $40.4M | $67.9M | $55.5M | $69.9M | $110.5M | $155.6M | $160.8M | $158.6M | $181.6M |
| Stocks | 0 | $10.8M | $16.1M | $19.3M | $18.7M | $15.9M | $21.8M | $30.6M | $23.2M | $79.6M |
| Actifs Courants | $261.3M | $249.1M | $320.9M | $779.3M | $1.23B | $954.4M | $693.8M | $1.22B | $1.37B | $2.27B |
| Immobilisations Corporelles | $7.4M | $8.4M | $12.7M | $35.2M | $118.2M | $130.0M | $175.0M | $179.0M | $117.7M | $135.4M |
| Goodwill | 0 | 0 | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M |
| Actifs Incorporels | 0 | $133.0M | $701.0M | $710.5M | $715.3M | $724.8M | $705.9M | $379.5M | $118.8M | $388.8M |
| Actifs Totaux | $269.3M | $391.7M | $1.12B | $1.62B | $2.21B | $1.94B | $1.71B | $1.90B | $1.71B | $2.90B |
| Dettes Fournisseurs | $6.3M | $15.3M | $6.0M | $10.3M | $18.7M | $23.0M | $27.3M | $6.0M | $17.3M | $45.5M |
| Dette à Court Terme | 0 | 0 | $11.7M | $20.0M | 0 | $208.8M | $72.1M | $194.3M | $257.8M | $569.6M |
| Passifs Courants | $49.6M | $82.0M | $166.8M | $235.9M | $277.3M | $509.3M | $406.2M | $603.1M | $581.0M | $968.4M |
| Dette à Long Terme | $98.2M | $145.0M | $141.3M | $293.9M | $309.1M | $956.6M | $1.26B | $1.90B | $2.11B | $2.03B |
| Passifs Totaux | $149.8M | $235.2M | $768.5M | $1.03B | $1.73B | $1.94B | $2.05B | $2.71B | $2.80B | $3.10B |
| Réserves | -$735.1M | -$814.1M | -$938.9M | -$1.19B | -$1.63B | -$2.10B | -$2.66B | -$3.28B | -$3.65B | -$2.96B |
| Capitaux Propres | $119.6M | $156.4M | $350.7M | $594.3M | $482.0M | $1.4M | -$347.1M | -$818.6M | -$1.10B | -$205.3M |
| Dette Totale | $98.2M | $145.0M | $153.0M | $328.0M | $420.4M | $1.27B | $1.46B | $2.23B | $2.47B | $2.71B |
| Dette Nette | -$133.4M | -$46.3M | -$74.6M | -$358.5M | -$683.2M | $496.0M | $1.05B | $1.35B | $1.33B | $761.7M |
| Fonds de Roulement | $211.7M | $167.0M | $154.1M | $543.4M | $954.4M | $445.0M | $287.5M | $615.5M | $784.5M | $1.31B |
Santé financière
| Dette / Capitaux propres | -4.21 |
| Ratio de liquidité | 3.39 |
Rentabilité
| Rentabilité des capitaux propres | 21.72% |
| Rentabilité du capital investi | 2.61% |
| Rentabilité des actifs | -1.18% |
| Marge brute | 82.14% |
| Marge opérationnelle | 11.52% |
| Marge nette | -3.80% |
Entreprises liées: ACLX · ALKS · ARWR · CRNX · KRYS · MTSR · PCVX
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de PTCT: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions